Blood Tests Tracking Melanoma in Patients Treated With Immunotherapy
Studies blood tests that track tumour DNA in advanced melanoma patients after immunotherapy.
Plain-language title generated from the registry record
Registry title: Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma
Key facts
- Where
- Chelsea, United KingdomSee the site
Where in United Kingdom
- The Royal MarsdenChelsea, United KingdomNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Royal Marsden NHS Foundation Trust
- Trial code
- NCT06710093
- Record updated
- 29 November 2024
- Original description
The advent of immune ICI has remarkably improved survival in advanced melanoma patients in the last decade. Long term responders following 2 years of treatment with immunotherapy go on to surveillance with frequent radiological imaging every 3-6 months up to 5-10 years. This not only exposes patients with a relatively low risk of recurrence to significant amounts of ionising radiation, but also increases the burden and cost on already stretched radiology departments. Therefore, this study aims to assess the feasibility and patient experience of using ctDNA with minimally invasive liquid biopsy assays as a biomarker for detecting disease relapse or progression at the point of radiological progression. Data from this pilot study will help to design a future validation study for establishing optimal liquid biopsy for surveillance in advanced melanoma patients.Read full original descriptionShow less
Power of Liquid Biopsy Tracking in Immunotherapy Treated Stage IV Melanoma
The advent of immune ICI has remarkably improved survival in advanced melanoma patients in the last decade. Long term responders following 2 years of treatment with immunotherapy go on to surveillance with frequent radiological imaging every 3-6 months up to 5-10 years. This not only exposes patients with a relatively low risk of recurrence to significant amounts of ionising radiation, but also increases the burden and cost on already stretched radiology departments. Therefore, this study aims to assess the feasibility and patient experience of using ctDNA with minimally invasive liquid biopsy assays as a biomarker for detecting disease relapse or progression at the point of radiological progression. Data from this pilot study will help to design a future validation study for establishing optimal liquid biopsy for surveillance in advanced melanoma patients.
Inclusion: Histologically proven melanoma; Unresectable stage III or stage IV disease, with confirmed radiological disease progression within 1 month of recruitment; Patient has received at least 1 cycle of immunotherapy with checkpoint inhibitors for melanoma; Undergoing standard of care active treatment with regular interval imaging or routine imaging surveillance following treatment completion/cessation; Age over 16; Not previously diagnosed with HIV, Hepatitis B or C (does not need testing).
Exclusion: Unable to comply with schedule of study samples to be collected. Concurrent active malignancies needing treatment; Unable to provide informed consent due to psychological, medical or cognitive conditions; Not on routine surveillance with interval imaging per standard of care.